Journal of Cataract & Refractive Surgery
Volume 33, Issue 9 , Pages 1539-1545 , September 2007

In vivo pharmacokinetics and in vitro pharmacodynamics of nepafenac, amfenac, ketorolac, and bromfenac

,Accepted 22 May 2007.

References 

  1. Flach AJ. Topical nonsteroidal anti-inflammatory drugs in ophthalmology. Int Ophthalmol Clin. 2002;42(1):1–11
  2. Miyake K, Masuda K, Shirato S, et al. Comparison of diclofenac and fluorometholone in preventing cystoid macular edema after small incision cataract surgery: a multicentered prospective trial. Jpn J Ophthalmol. 2000;44:58–67
  3. Solomon LD. Efficacy of topical flurbiprofen and indomethacin in preventing pseudophakic cystoid macular edema; the Flurbiprofen-CME Study Group I. J Cataract Refract Surg. 1995;21:73–81
  4. O'Brien TP. Emerging guidelines for use of NSAID therapy to optimize cataract surgery patient care. Curr Med Res Opin. 2005;21:1131–1137erratum, 1431–1432
  5. Price MO, Price FW. Efficacy of topical ketorolac tromethamine 0.4% for control of pain or discomfort associated with cataract surgery. Curr Med Res Opin. 2004;20:2015–2019
  6. Flach AJ. Nonsteroidal anti-inflammatory drugs. In:  Tasman W editors. Duane's Foundations of Clinical Ophthalmology. vol. 3:Philadelphia, PA: Lippincott; 1994;chapter 38
  7. Heier JS, Topping TM, Baumann W, et al. Ketorolac versus prednisolone versus combination therapy in treatment of acute pseudophakic cystoid macular edema. Ophthalmology. 2000;107:2034–2038discussion by AJ Flach, 2039
  8. Gamache DA, Graff G, Brady MT, et al. Nepafenac, a unique nonsteroidal prodrug with potential utility in the treatment of trauma-induced ocular inflammation: I. Assessment of anti-inflammatory efficacy. Inflammation. 2000;24:357–370
  9. Ke T-L, Graff G, Spellman JM, Yanni JM. Nepafenac, a unique nonsteroidal prodrug with potential utility in the treatment of trauma-induced ocular inflammation: II. In vitro bioactivation and permeation of external ocular barriers. Inflammation. 2000;24:371–384
  10. Kim DH, Stark WJ, O'Brien TP, Dick JD. Aqueous penetration and biological activity of moxifloxacin 0.5% ophthalmic solution and gatifloxacin 0.3% solution in cataract surgery patients. Ophthalmology. 2005;112:1992–1996
  11. Nedelman JR, Gibiansky E, Lau DTW. Applying Bailer's method for AUC confidence intervals to sparse sampling. Pharm Res. 1995;12:124–128erratum 1996; 13:183
  12. Lindstrom R, Kim T. Ocular permeation and inhibition of retinal inflammation: an examination of data and expert opinion on the clinical utility of nepafenac. Curr Med Res Opin. 2006;22:397–404erratum, 1237
  13. Copeland RA, Williams JM, Giannaras J, et al. Mechanism of selective inhibition of the inducible isoform of prostaglandin G/H synthase. Proc Natl Acad Sci USA. 1994;91:11202–11206
  14. Bellot JL, Palmero M, Garcia-Cabanes C, et al. Additive effect of nitric oxide and prostaglandin-E2 synthesis inhibitors in endotoxin-induced uveitis in the rabbit. Inflamm Res. 1996;45:203–208
  15. Bucci FA, Waterbury LD, Amico LM. Prostaglandin E2 inhibition and aqueous concentration of ketorolac 0.4% (Acular LS) and nepafenac 0.1% (Nevanac) in patients undergoing phacoemulsification. Am J Ophthalmol. 2007;144:146–147
  16. Fleisher LN, McGahan MC. Time course for prostaglandin synthesis by rabbit lens during endotoxin-induced ocular inflammation. Curr Eye Res. 1986;5:629–634
  17. Herbort CP, Okumura A, Mochizuki M. Endotoxin-induced uveitis in the rat; a study of the role of inflammation mediators. Graefes Arch Clin Exp Ophthalmol. 1988;226:553–558
  18. Csukas S, Paterson CA, Brown K, Bhattacherjee P. Time course of rabbit ocular inflammatory response and mediator release after intravitreal endotoxin. Invest Ophthalmol Vis Sci. 1990;31:382–387
  19. Okumura A, Mochizuki M, Nishi M, Herbort CP. Endotoxin-induced uveitis (EIU) in the rat: a study of inflammatory and immunological mechanisms. Int Ophthalmol. 1990;14:31–36
  20. Waterbury LD, Silliman D, Jolas T. Comparison of cyclooxygenase inhibitory activity and ocular anti-inflammatory effects of ketorolac tromethamine and bromfenac sodium. Curr Med Res Opin. 2006;22:1133–1140
  21. Dubois RN, Abramson SB, Crofford L, et al. Cyclooxygenase in biology and disease. FASEB J. 1998;12:1063–1073
  22. Oka T, Shearer TR, Azuma M. Involvement of cyclooxygenase-2 in rat models of conjunctivitis. Curr Eye Res. 2004;29:27–34
  23. Guex-Crosier Y. Anti-inflammatoires non stéroïdiens (AINS) et inflammation oculaire. [Non-steroidal anti-inflammatory drugs and ocular inflammation.]. Klin Monatsbl Augenheilkd. 2001;218:305–308
  24. Bonazzi A, Mastyugin V, Mieyal PA, et al. Regulation of cyclooxygenase-2 by hypoxia and peroxisome proliferators in the corneal epithelium. J Biol Chem. 2000;275:2837–2844
  25. Masferrer JL, Kulkarni PS. Cyclooxygenase-2 inhibitors: a new approach to the therapy of ocular inflammation. Surv Ophthalmol. 1997;41(suppl 2):S35–S40
  26. Lane SS, Modi SS, Lehmann RP, Holland EJ. Nepafenac ophthalmic suspension 0.1% for the prevention and treatment of ocular inflammation associated with cataract surgery. J Cataract Refract Surg. 2007;33:53–58

 Dr. Raizman is a consultant to Alcon Laboratories, Inc. Drs. Walters, Ernest, Gayton, and Lehmann have received gifts in kind, honoraria, or travel reimbursement valued at over $1000 from Alcon Laboratories, Inc., in the past 12 months. No author has a financial or proprietary interest in any material or method mentioned.Financial support from Alcon Laboratories, Inc., Fort Worth, Texas, USA.

PII: S0886-3350(07)00991-1

doi: 10.1016/j.jcrs.2007.05.015

Journal of Cataract & Refractive Surgery
Volume 33, Issue 9 , Pages 1539-1545 , September 2007

Article Tools

* Image Usage & Resolution